These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2185 related articles for article (PubMed ID: 15107948)

  • 1. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer in limited-resource countries: treatment and allocation of resources.
    Eniu A; Carlson RW; Aziz Z; Bines J; Hortobágyi GN; Bese NS; Love RR; Vikram B; Kurkure A; Anderson BO;
    Breast J; 2006; 12 Suppl 1():S38-53. PubMed ID: 16430398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
    Colozza M; de Azambuja E; Cardoso F; Bernard C; Piccart MJ
    Oncologist; 2006 Feb; 11(2):111-25. PubMed ID: 16476832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of metastatic breast carcinoma].
    Puglisi F; Sobrero A
    Ann Ital Chir; 1999; 70(3):377-89. PubMed ID: 10466241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The choice of systemic adjuvant therapy in receptor-positive early breast cancer.
    Dellapasqua S; Castiglione-Gertsch M
    Eur J Cancer; 2005 Feb; 41(3):357-64. PubMed ID: 15691634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
    Anderssona M; Awadab A; Barrett-Leec P; Ellisd P; Hupperetse P; Jackischf C; Kubistag E; Lückh HJ; Monnerati C; Nitzj U; Untchl M
    Breast; 2008 Feb; 17 Suppl 2():S1-S12. PubMed ID: 18439963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer.
    Shenkier T; Weir L; Levine M; Olivotto I; Whelan T; Reyno L;
    CMAJ; 2004 Mar; 170(6):983-94. PubMed ID: 15023926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.
    Aapro MS
    Oncologist; 2001; 6(4):376-85. PubMed ID: 11524557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 110.